Clinical trials: Neoplasms, Pharyngeal
Nasopharyngeal Carcinoma, Neoadjuvant Therapy
PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this Phase II, Multicenter, Randomized Controlled Clinical Trial is to evaluate the efficacy and safety of PD-1 inhibitor Plus GP chemotherapy as Neoadjuvant Therapy in the Treatment of Locoregionally Advanced…
- Conditions
- Nasopharyngeal Carcinoma, Neoadjuvant Therapy, PD-1 Inhibitor
- Trial name
- NeoTurbo (NCT05340270)
- Testing
- PD-1 inhibitor+GP, GP
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Guangxi Medical University
Nasopharyngeal Carcinoma
Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma
In this multicenter, prospective, randomized, controlled, non-inferiority Phase III clinical trial, treatment-naïve patients with nasopharyngeal carcinoma (NPC) without metastasis will be enrolled for curative radiotherapy.
- Trial name
- OART (NCT06516133)
- Testing
- Intensity modulated radiation therapy (IMRT) with conventional planning target volume (PTV) margin and without online adaptive radiotherapy, Chemotherapy, Intensity modulated radiation therapy (IMRT) with smaller planning target volume (PTV) margin and online adaptive radiotherapy
- Where
- China
- Volunteers
- 494 people
- Sponsor
- Sun Yat-sen University
Oropharyngeal Carcinoma
Off-line Adaptive Proton Therapy
This prospective in-silico study evaluates a novel Off-line Adaptive Proton Therapy (o-APT) workflow for patients with oropharyngeal cancer receiving proton therapy.
- Trial name
- o-APT (NCT07866547)
- Testing
- Off-line Adaptive Proton Therapy (o-APT) Workflow Evaluation
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- University Medical Center Groningen
Renal Cancer, Renal Clear Cell Carcinoma
CD70-targeted immunoPET Imaging of Malignant Cancers
This study aims to determine the value of cluster of differentiation (CD70)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging for diagnosing human malignancies, including renal cell carcinoma…
- Conditions
- Renal Cancer, Renal Clear Cell Carcinoma, Lymphoma, Lymphoma, Large B-Cell, Diffuse
- Trial name
- NCT06852638
- Testing
- [18F]F-RESCA-RCCB6, [18F]F-RESCA-R8B4, [68Ga]Ga-NOTA-R8B4
- Where
- China
- Volunteers
- 300 people
- Sponsor
- RenJi Hospital
Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
Phase II: To explore the efficacy, safety and tolerability of BL-B01D1+SI-B003 in patients with locally advanced or metastatic non-small cell lung cancer and nasopharyngeal carcinoma, and to further explore the optimal dose and…
- Trial name
- NCT05956587
- Testing
- BL-B01D1, SI-B003
- Where
- 16 sites in China
- Volunteers
- 121 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Nasopharyngeal Cancer
Dendritic Cell Therapy With CD137L-DC-EBV-VAX in Locally Advanced Stage IV or Locally Recurrent/Metastatic Nasopharyngeal Carcinoma
This study is carried out to find out the safety and recommended dose of CD137L-DC-EBV-VAX in nasopharyngeal cancer. CD137L-DC-EBV-VAX is a product made from one of our own immune system cells (dendritic cell, DC).
- Trial name
- NCT03282617
- Testing
- CD137L-DC-EBV-VAX
- Where
- Singapore
- Volunteers
- 55 people
- Sponsor
- National University Hospital, Singapore
Nasopharyngeal Carcinoma
Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma
Through open-label, single-center, randomised clinical trials, we intend to demonstrate that PD-1 treatment added to salvage surgery could further decrease the rate of disease progression and improve the survival outcome of…
- Trial name
- NCT05092217
- Testing
- Tirelizumab, salvage surgery
- Volunteers
- 80 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Esophageal Cancer
a Multicentric Randomized Controlled Trial of Self-Expandable Esophageal Radiation Stent
Esophageal cancer is common in some areas , ranking as the fourth leading cause of death from cancer in China and sixth worldwide.
- Trial name
- NCT01054274
- Testing
- novel stent, conventional covered stent
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Southeast University, China
Laryngeal Cancer, Hypopharynx Cancer
Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma
The aim of this study is to define whether combination of induction chemotherapy and PD-1 inhibitor (Toripalimab) improve the rate of larynx preservation, for patients with resectable laryngeal/hypopharyngeal carcinoma.
- Conditions
- Laryngeal Cancer, Hypopharynx Cancer, Laryngeal Neoplasms
- Trial name
- INSIGHT (NCT04995120)
- Testing
- chemotherapy TP regimen combined with Toripalimab
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Fudan University
Nasopharyngeal Carcinoma
Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma
A total of 120 patients with pathologically confirmed locally advanced low-risk nasopharyngeal carcinoma were enrolled. They were randomly divided into two groups, with 60 patients in each group.
- Trial name
- NCT02237924
- Testing
- endostar, DDP, IMRT
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Nasopharyngeal Carcinoma
Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
This is a multicenter, open-label, randomized, controlled, phase III trial. The purpose of this trial is to evaluate the efficacy and toxicity of anti-PD-1 antibody combined with chemoradiotherapy versus chemoradiotherapy alone…
- Trial name
- NCT05340491
- Testing
- Toripalimab, Chemotherapy, Intensity modulated radiotherapy
- Where
- 12 sites in China
- Volunteers
- 212 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma
This is a multi-center, randomized, open-label, phase II study to evaluate the efficacy and safety of anti-PD-1 antibody Penpulimab (AK105) combined with chemotherapy ± anlotinib hydrochloride in the first-line treatment of…
- Trial name
- NCT04736810
- Testing
- AK105, Cisplatin, Gemcitabine
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Akeso
Nasopharyngeal Carcinoma
Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy
The goal of this multicenter randomized non-inferior study is to compare the additon of camrelizumab or nimotuzumab to neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma…
- Trial name
- NCT05772208
- Testing
- Camrelizumab, Nimotuzumab, neoadjuvant chemotherapy and CCRT
- Where
- China
- Volunteers
- 459 people
- Sponsor
- Fudan University
HPV Positive Cancer, Vulvar, Vaginal, Penile, Rectal Cancer
HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers
Background: For some cancers associated with human papillomavirus (HPV), standard treatments are not helpful. Researchers want to see if a vaccine for HPV combined with a drug called M7824 (MSB0011359C) has a better effect on…
- Conditions
- HPV Positive Cancer, Vulvar, Vaginal, Penile, Rectal Cancer, Anal Cancer, Oropharyngeal Cancer
- Trial name
- NCT04432597
- Testing
- PRGN-2009, M7824, EKG
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer, Nasopharynx Cancer
The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers
Cancer care for head and neck cancers is multidisciplinary and complex and knowledge on the rare ones is limited. There is a wide consensus that to support clinical research on rare cancers, clinical registries should be…
- Conditions
- Head and Neck Cancer, Nasopharynx Cancer, Nasal Cavity and Paranasal Sinus Cancer, Salivary Gland Cancer
- Trial name
- EURACAN (NCT05483374)
- Testing
- observation
- Where
- 10 sites in Czechia, Germany and 1 more
- Volunteers
- 13,600 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Current Smoker, Head and Neck Squamous Cell Carcinoma
Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy
This pilot randomized clinical trial studies how well bupropion hydrochloride works compared with patient's choice for quitting smoking in patients with squamous cell head and neck cancer undergoing radiation therapy with or…
- Conditions
- Current Smoker, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma
- Trial name
- NCT02582008
- Testing
- Bupropion Hydrochloride, Laboratory Biomarker Analysis, Nicotine Replacement
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Wake Forest University Health Sciences
Nasopharyngeal Carcinoma
Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma
This is a Phase Ⅲ randomized, controlled, multi-center, trial comparing cisplatin plus docetaxel to cetuximab, cisplatin, and docetaxel induction chemotherapy followed by concurrent chemoradiation in previously untreated patients…
- Trial name
- NCT02633176
- Testing
- Cetuximab, Cisplatin, Docetaxel
- Where
- 10 sites in China
- Volunteers
- 120 people
- Sponsor
- Sun Yat-sen University
Multi-omics Technique, Nasopharyngeal Carcinoma
Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC
The observational clinical study will recruit 50 recurrent and/or metastatic nasopharyngeal carcinoma (r/mNPC) patients, to investigate the prediction values of multi-omics technique for the efficacy of chemoradiotherapy combined…
- Conditions
- Multi-omics Technique, Nasopharyngeal Carcinoma, Recurrent and Metastatic Nasopharyngeal Carcinoma, Efficacy of Chemoradiotherapy and Immunotherapy
- Trial name
- NCT06197776
- Testing
- cisplatin-based chemoradiotherapy combined with immunotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Squamous Cell, Oral Cancer
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
Participants in this study have a type of cancer called squamous cell carcinoma of the head and neck (SCCHN). Their SCCHN has spread around the area where the cancer first started. This is called locally-advanced SCCHN.
- Conditions
- Carcinoma, Squamous Cell, Oral Cancer, Oropharynx Cancer, Larynx Cancer
- Trial name
- NCT03174275
- Testing
- Durvalumab, Carboplatin, Nab-paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Oncology, Radiology
Upfront Neck Dissection Before Radiotherapy in Stage N3 Nasopharyngeal Carcinoma: A Retrospective Study
This retrospective observational study aims to evaluate the association between neck tumor burden and high-risk imaging features with locoregional recurrence and distant metastasis in patients with stage N3 nasopharyngeal…
- Trial name
- NCT07180173
- Testing
- Salvage Neck Treatment
- Where
- Taiwan
- Volunteers
- 7 people
- Sponsor
- Taichung Veterans General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.